Market research
UNCY Unicycive Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 131M
- P/E ratio
- Not available
- Analyst target
- 29.6
- Dividend yield
- Not available
- Beta
- 1.78
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US90466Y2028
- Market cap
- 131M
- P/E ratio
- Not available
- Analyst target
- 29.6
- Dividend yield
- Not available
- Beta
- 1.78
About
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the UNCY discussion.
No comments yet
Start a focused discussion about UNCY.